Information about the General Meeting on 23 December 2019
Information about shareholder meetings can be found in this section, including the upcoming General Meeting that will be held on 23 December 2019 to approve the proposed fundraise of approximately $50 million, board restructuring and AIM delisting. Please click on the link below for more information.
On 6 December 2019, Summit Therapeutics announced a proposed fundraising of ~$50 million through a subscription and placing of new ordinary shares and warrants to existing investors. The transaction also includes proposals to restructure the Company’s board of directors and to cancel the trading on AIM of the Company’s ordinary shares. The Company’s American Depositary Shares (“ADS”) will remain listed on Nasdaq, where one ADS is represented by five ordinary shares.
The transaction is subject to shareholder approval at a General Meeting that will be held at the offices of CMS Cameron McKenna Nabarro Olswang LLP at Cannon Place, 78 Cannon Street, London, EC4N 6AF at 10:30 a.m. on 23 December 2019.
A copy of the Shareholder Circular is available for download:
Shareholder Circular (pdf)
Summit Therapeutics held its Annual General Meeting of shareholders at Pewterers’ Hall, Oat Lane, London, EC2V 7DE at 10:00 a.m. on 19 June 2019.
The Notice of Annual General Meeting that contained details of the resolution considered by shareholders at the AGM, the results of the proxy votes lodged by shareholders in advance of the AGM along with the UK Annual Report and Accounts are available below.